A LinkedIn post from Forge Biologics highlights the role of power infrastructure in the company’s gene therapy manufacturing operations. The post notes that Forge’s flywheel Uninterruptible Power Supply system is described as capable of generating enough power to supply 32,000 homes for an hour, underscoring a focus on redundancy and reliability.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post further points to comments from Mark Galinato about designing “the Hearth,” Forge’s manufacturing facility, with resilience at its core to support uninterrupted operations. For investors, this emphasis on robust utilities suggests ongoing capital investment in infrastructure that may support higher uptime, operational continuity, and regulatory confidence, potentially strengthening Forge’s competitive position in contract gene therapy manufacturing.
By drawing attention to power reliability, the post implies that Forge is positioning its facility as a de-risked partner for biotech and pharmaceutical clients seeking secure production capacity for gene therapies. While the post is promotional in tone, the underlying message aligns with industry trends in which supply-chain robustness and business continuity are increasingly central to vendor selection and long-term client relationships.